AVITA Medical's Cohealyx Study Slashes Skin Grafting Time by Nearly 20 Days
RCEL sits 58% above its 52-week low of $3.22.
Summary
AVITA Medical announced highly positive interim results from its Cohealyx-I multi-center study, showing a statistically superior reduction of nearly 20 days in mean time to skin grafting for full-thickness wounds (13.6 days vs. 33.2 days benchmark, p<0.001). This significant clinical advancement for Cohealyx, a collagen-based dermal matrix, suggests a substantial improvement in wound care efficiency and patient outcomes. For AVITA Medical, a small-cap company that recently disclosed a 'going concern' warning in its 10-K, these strong product development results are highly material, potentially bolstering its commercial viability and long-term financial health. The company plans to present this data and host an analyst webinar, which will be a key event for investors to assess the product's market potential and regulatory path forward.
At the time of this announcement, RCEL was trading at $5.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $150.4M. The 52-week trading range was $3.22 to $10.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.